Ion Beam ApplicationsIOBCF 82 Debt-to-EBITDA is 2.60 as of Dec. 2025, which is 10% below its 10-year median of 2.88. GuruFocus rates IOBCF with a GF Score™ of 82/100 and a GF Value™ of $18.58 (Fairly Valued). The stock has 10 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Ion Beam Applications ranks worse than 71.79% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ion Beam Applications's Debt-to-EBITDA or its related term are showing as below:
IOBCF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.61 Med: 2.88 Max: 12.19
Current: 3.2
During the past 13 years, the highest Debt-to-EBITDA Ratio of Ion Beam Applications was 12.19. The lowest was -2.61. And the median was 2.88.
IOBCF's Debt-to-EBITDA is ranked worse than 71.79% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs IOBCF: 3.20
Ion Beam Applications (OTCPK:IOBCF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ion Beam Applications Debt-to-EBITDA Related Terms
Ion Beam Applications Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ion Beam Applications's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Ion Beam Applications's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ion Beam Applications Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ion Beam Applications's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ion Beam Applications's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Ion Beam Applications (IOBCF) has a Debt-to-EBITDA of 2.60 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ion Beam Applications. This is 10% below median its historical median of 2.88. According to the industry distribution chart, Ion Beam Applications ranks #336 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 71.8%.
Is Ion Beam Applications' Debt-to-EBITDA too high?
Ion Beam Applications' current Debt-to-EBITDA of 2.60 is 10% below median its 10-year median of 2.88. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. Ion Beam Applications' value of 2.60 is 67.2% above this industry median. Based on the distribution chart, Ion Beam Applications ranks #336 out of 468 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Ion Beam Applications has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ion Beam Applications' Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Ion Beam Applications ranks #336 out of 468 companies for Debt-to-EBITDA. This places Ion Beam Applications in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. Ion Beam Applications' value of 2.60 is 67.2% above this benchmark. While the company's 10-year median is 2.88 vs. the industry median of 1.56, Ion Beam Applications has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ion Beam Applications's current Debt-to-EBITDA of 2.60 is 67.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ion Beam Applications. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ion Beam Applications's current Debt-to-EBITDA is 2.60, which is 10% below median its own 10-year median of 2.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ion Beam Applications stock overvalued right now?
Based on GuruFocus' analysis, Ion Beam Applications (IOBCF) is currently considered Fairly Valued. The stock's GF Value™ is $18.58, compared to a current price of $18.86 — trading 1.5% above its estimated fair value. The current Debt-to-EBITDA is 2.60, which is 10% below median its 10-year median of 2.88 and 67.2% above the Medical Devices & Instruments industry median of 1.56. Ion Beam Applications' overall GF Score™ is 82/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ion Beam Applications (IOBCF), the current Debt-to-EBITDA is 2.60 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ion Beam Applications (IOBCF) Overvalued in 2026?
Based on GuruFocus' analysis, Ion Beam Applications stock appears to be overvalued.
The current stock price of $18.86 is trading 1.5% above its estimated GF Value™ of $18.58.
GuruFocus considers Ion Beam Applications to be Fairly Valued.
Key valuation signals for IOBCF:
Debt-to-EBITDA: 2.60 (10% below median its 10-year median of 2.88)
GF Value™: $18.58 vs. price of $18.86 (1.5% above fair value)
Industry Position: 67.2% above the Medical Devices & Instruments median (#336 of 468)
No single metric tells the full story. See the IOBCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in three segments: IBA Clinical, including Proton Therapy and Dosimetry; IBA Technologies; and IBA Corporate. Proton therapy and other accelerators contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, China, Germany, and India.
82GF Score
Get the complete analysis for IOBCF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IOBCF has been successfully added to your 
